Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Certolizumab pegol Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Single-dose vial
  • 1.4.3 Single-dose prefilled syringe
• 1.5 Market by Application
  • 1.5.1 Global Certolizumab pegol Market Share by Application (2014-2025)
  • 1.5.2 Crohn’s disease
  • 1.5.3 Active rheumatoid arthritis
  • 1.5.4 Active psoriatic arthritis
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Certolizumab pegol Market Size
• 2.2 Certolizumab pegol Growth Trends by Regions
  • 2.2.1 Certolizumab pegol Market Size by Regions (2014-2025)
  • 2.2.2 Certolizumab pegol Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Certolizumab pegol Market Size by Manufacturers
  • 3.1.1 Global Certolizumab pegol Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Certolizumab pegol Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Certolizumab pegol Market Concentration Ratio (CR5 and HHI)
• 3.2 Certolizumab pegol Key Players Head office and Area Served
• 3.3 Key Players Certolizumab pegol Product/Solution/Service
• 3.4 Date of Enter into Certolizumab pegol Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Certolizumab pegol Market Size by Type (2014-2019)
• 4.2 Global Certolizumab pegol Market Size by Application (2014-2019)

5 United States

• 5.1 United States Certolizumab pegol Market Size (2014-2019)
• 5.2 Certolizumab pegol Key Players in United States
• 5.3 United States Certolizumab pegol Market Size by Type
• 5.4 United States Certolizumab pegol Market Size by Application

6 Europe

• 6.1 Europe Certolizumab pegol Market Size (2014-2019)
• 6.2 Certolizumab pegol Key Players in Europe
• 6.3 Europe Certolizumab pegol Market Size by Type
• 6.4 Europe Certolizumab pegol Market Size by Application

7 China

• 7.1 China Certolizumab pegol Market Size (2014-2019)
• 7.2 Certolizumab pegol Key Players in China
• 7.3 China Certolizumab pegol Market Size by Type
• 7.4 China Certolizumab pegol Market Size by Application

8 Japan

• 8.1 Japan Certolizumab pegol Market Size (2014-2019)
• 8.2 Certolizumab pegol Key Players in Japan
• 8.3 Japan Certolizumab pegol Market Size by Type
• 8.4 Japan Certolizumab pegol Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Certolizumab pegol Market Size (2014-2019)
• 9.2 Certolizumab pegol Key Players in Southeast Asia
• 9.3 Southeast Asia Certolizumab pegol Market Size by Type
• 9.4 Southeast Asia Certolizumab pegol Market Size by Application

10 India

• 10.1 India Certolizumab pegol Market Size (2014-2019)
• 10.2 Certolizumab pegol Key Players in India
• 10.3 India Certolizumab pegol Market Size by Type
• 10.4 India Certolizumab pegol Market Size by Application

11 Central & South America

• 11.1 Central & South America Certolizumab pegol Market Size (2014-2019)
• 11.2 Certolizumab pegol Key Players in Central & South America
• 11.3 Central & South America Certolizumab pegol Market Size by Type
• 11.4 Central & South America Certolizumab pegol Market Size by Application

12 International Players Profiles

• 12.1 UCB
  • 12.1.1 UCB Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Certolizumab pegol Introduction
  • 12.1.4 UCB Revenue in Certolizumab pegol Business (2014-2019)
  • 12.1.5 UCB Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Certolizumab pegol (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
In 2018, the global Certolizumab pegol market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Certolizumab pegol status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Certolizumab pegol development in United States, Europe and China.

The key players covered in this study
UCB
...

Market segment by Type, the product can be split into
Single-dose vial
Single-dose prefilled syringe

Market segment by Application, split into
Crohn’s disease
Active rheumatoid arthritis
Active psoriatic arthritis

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Certolizumab pegol status, future forecast, growth opportunity, key market and key players.
To present the Certolizumab pegol development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Certolizumab pegol are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.